|
Median age, years (range)
|
54.0 (25–78)
|
55.0 (27–77)
|
54.0 (25–78)
| |
|
Diagnosis, n (%)
|
|
Metastatic
|
214
|
(73.0)
|
44
|
(66.7)
|
170
|
(74.9)
|
0.21
|
|
Locally advanced
|
79
|
(27.0)
|
22
|
(33.3)
|
57
|
(25.1)
|
|
Sites of metastases, n (%)
| | | | | | | |
|
Lung
|
71
|
(24.2)
|
16
|
(24.2)
|
55
|
(24.2)
|
1.00
|
|
Liver
|
58
|
(19.8)
|
20
|
(30.3)
|
38
|
(16.7)
|
0.02*
|
|
Bone
|
155
|
(52.9)
|
35
|
(53.0)
|
120
|
(52.9)
|
1.00
|
|
CNS
|
14
|
(4.8)
|
3
|
(0.5)
|
11
|
(4.8)
|
1.00
|
|
Soft tissue
|
185
|
(63.2)
|
44
|
(66.7)
|
141
|
(62.1)
|
0.56
|
|
Treatment regimens, n (%)
|
|
Anthracycline-based regimen for EBC
|
79
|
(27.0)
|
22
|
(33.3)
|
57
|
(25.1)
| |
|
Anthracycline-based regimen for MBC
|
135
|
(46.1)
|
26
|
(39.4)
|
109
|
(48.0)
| |
|
Taxane-based regimen for EBC
|
39
|
(13.3)
|
18
|
(27.3)
|
21
|
(9.3)
| |
|
Taxane-based regimen for MBC
|
228
|
(77.8)
|
53
|
(80.3)
|
175
|
(77.1)
| |
|
Eribulin as first-/second-line for MBC
|
31
|
(47.0)
|
31
|
(47.0)
|
–
| |
|
Taxane-based regimen prior to eribulin
|
40
|
(13.7)
|
40
|
(60.6)
|
–
| |
